Most infants hospitalised for RSV-related infections need oxygen support and critical care despite nirsevimab use, with ...

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe ...

Here's what RSV is, why it especially impacts the youngest and oldest members of society and how it is usually treated.

Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, ...

A monoclonal antibody -- a protein created in a lab which mimics the work of a natural antibody -- could be highly effective ...

A recent study revealed that newborns can be easily protected against respiratory syncytial virus infection by using the ...

For a broader group of infants—0 to 7 months old—RSV-NET showed a 43 percent drop in hospitalizations in the 2024–2025 RSV season, and NVSN saw a 28 percent drop. Again, when Houston was excluded from ...

A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...

A meta-analysis indicates that the monoclonal antibody nirsevimab offers significant real-world protection against severe ...

The U.S. Centers for Disease Control and Prevention (CDC) recommends that all babies be protected from RSV by one of two ...